leadf
logo-loader
viewAdalta Ltd

AdAlta targeting human trials for lead i-body fibrosis candidate in under a year

AdAlta Ltd (ASX: 1AD) CEO Sam Cobb speaks to Proactive Investors about the biotech's i-body technology platform and pipeline of i-bodies; including its lead candidate for treating fibrotic diseases, in particular Idiopathic Pulmonary Fibrosis, AD-214.

A phase I human study is expected to begin in January 2020.

Quick facts: Adalta Ltd

Price: 0.115 AUD

ASX:1AD
Market: ASX
Market Cap: $28.2 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Adalta Ltd named herein, including the promotion by the Company of Adalta Ltd in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Tony Locantro says stocks now falling to 'decent values' amidst market...

Alto Capital's Tony Locantro says we're now seeing some long overdue volatility in the market and stocks falling to decent values. ''We had the Dow Jones up above 28,000, we had gold knocking on US$2000, both of those were extremely crowded trades''. ''We had the NASDAQ at stupid levels as well...

on 27/9/20

2 min read